AC Immune (ACIU) Competitors $2.43 0.00 (0.00%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$2.44 +0.01 (+0.62%) As of 07/25/2025 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACIU vs. QURE, SNDX, TRVI, MENS, NAGE, XERS, NUVB, MAZE, CRON, and KALVShould you be buying AC Immune stock or one of its competitors? The main competitors of AC Immune include uniQure (QURE), Syndax Pharmaceuticals (SNDX), Trevi Therapeutics (TRVI), Jyong Biotech (MENS), Niagen Bioscience (NAGE), Xeris Biopharma (XERS), Nuvation Bio (NUVB), Maze Therapeutics (MAZE), Cronos Group (CRON), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical products" industry. AC Immune vs. Its Competitors uniQure Syndax Pharmaceuticals Trevi Therapeutics Jyong Biotech Niagen Bioscience Xeris Biopharma Nuvation Bio Maze Therapeutics Cronos Group KalVista Pharmaceuticals uniQure (NASDAQ:QURE) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends. Which has more risk and volatility, QURE or ACIU? uniQure has a beta of 0.08, meaning that its share price is 92% less volatile than the S&P 500. Comparatively, AC Immune has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Which has preferable valuation and earnings, QURE or ACIU? AC Immune has higher revenue and earnings than uniQure. AC Immune is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatiouniQure$27.12M30.52-$239.56M-$4.39-3.44AC Immune$31.02M7.87-$57.83M-$0.58-4.19 Does the media favor QURE or ACIU? In the previous week, uniQure had 1 more articles in the media than AC Immune. MarketBeat recorded 2 mentions for uniQure and 1 mentions for AC Immune. AC Immune's average media sentiment score of 1.91 beat uniQure's score of 0.93 indicating that AC Immune is being referred to more favorably in the news media. Company Overall Sentiment uniQure Positive AC Immune Very Positive Do institutionals & insiders hold more shares of QURE or ACIU? 78.8% of uniQure shares are owned by institutional investors. Comparatively, 51.4% of AC Immune shares are owned by institutional investors. 4.8% of uniQure shares are owned by insiders. Comparatively, 4.6% of AC Immune shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is QURE or ACIU more profitable? AC Immune has a net margin of -177.79% compared to uniQure's net margin of -1,077.05%. AC Immune's return on equity of -44.60% beat uniQure's return on equity.Company Net Margins Return on Equity Return on Assets uniQure-1,077.05% -483.87% -34.28% AC Immune -177.79%-44.60%-22.25% Do analysts recommend QURE or ACIU? uniQure currently has a consensus price target of $37.82, suggesting a potential upside of 150.29%. AC Immune has a consensus price target of $12.00, suggesting a potential upside of 393.83%. Given AC Immune's stronger consensus rating and higher possible upside, analysts clearly believe AC Immune is more favorable than uniQure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score uniQure 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 2.91AC Immune 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAC Immune beats uniQure on 10 of the 17 factors compared between the two stocks. Get AC Immune News Delivered to You Automatically Sign up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACIU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACIU vs. The Competition Export to ExcelMetricAC ImmuneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$244M$3.06B$5.69B$9.50BDividend YieldN/A2.37%4.58%4.01%P/E Ratio-4.1921.1828.1020.05Price / Sales7.87288.50432.4490.07Price / CashN/A42.7636.2258.56Price / Book1.888.378.665.87Net Income-$57.83M-$55.19M$3.25B$258.55M7 Day Performance17.39%5.88%4.23%3.74%1 Month Performance16.27%17.33%10.52%11.75%1 Year Performance-37.85%4.42%34.41%18.03% AC Immune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACIUAC Immune2.0651 of 5 stars$2.43flat$12.00+393.8%-37.9%$244M$31.02M-4.19140Positive NewsQUREuniQure2.2039 of 5 stars$14.50-3.3%$37.82+160.8%+76.3%$821.09M$27.12M-3.30500Upcoming EarningsSNDXSyndax Pharmaceuticals3.5291 of 5 stars$9.73+2.9%$34.10+250.5%-60.9%$814.01M$23.68M-2.52110Positive NewsTRVITrevi Therapeutics3.8823 of 5 stars$6.82-0.6%$20.88+206.1%+148.3%$804.63MN/A-15.1620MENSJyong BiotechN/A$11.00+4.3%N/AN/A$802.09MN/A0.0031Quiet Period ExpirationNAGENiagen Bioscience1.4378 of 5 stars$9.68-4.7%$13.22+36.6%N/A$800.69M$99.60M56.94120XERSXeris Biopharma4.006 of 5 stars$5.14+0.6%$6.25+21.6%+96.5%$799.12M$203.07M-17.13290News CoverageNUVBNuvation Bio1.8636 of 5 stars$2.36+2.4%$7.17+204.3%-32.3%$782.60M$7.87M-1.0060News CoverageAnalyst UpgradeMAZEMaze TherapeuticsN/A$16.66-6.3%$23.50+41.1%N/A$778.71M$167.50M0.00121News CoverageAnalyst ForecastLockup ExpirationAnalyst RevisionGap UpHigh Trading VolumeCRONCronos Group1.9825 of 5 stars$2.09+4.0%N/A-15.3%$775.22M$117.61M16.08450News CoverageKALVKalVista Pharmaceuticals3.9681 of 5 stars$15.56+1.1%$26.29+68.9%+1.3%$768.79MN/A-4.22100 Related Companies and Tools Related Companies uniQure Competitors Syndax Pharmaceuticals Competitors Trevi Therapeutics Competitors Jyong Biotech Competitors Niagen Bioscience Competitors Xeris Biopharma Competitors Nuvation Bio Competitors Maze Therapeutics Competitors Cronos Group Competitors KalVista Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACIU) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon Musk: “This will transform civilization as we know it.”Robots are no longer science fiction — they’re the next trillion-dollar megatrend. According to Forbes, by ...Weiss Ratings | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AC Immune Please log in to your account or sign up in order to add this asset to your watchlist. Share AC Immune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
